Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
The present invention provides treatment of fatty liver disease using a class of pyrimidinedione cyclohexyl compounds.
1. A method of treating fatty liver disease, comprising:
administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula Id for said fatty liver disease, thereby treating the fatty liver disease,
wherein said administering comprises oral administration of said compound of Formula Id, wherein the compound of Formula Id has the structure:
wherein
each R 1a is independently H, C 1-6 alkyl, halogen, or C 1-6 haloalkyl;
R 2 is H, or C 1-6 alkyl; and
each R 4 is H, C 1-6 alkyl, halogen, or C 1-6 haloalkyl;
or salts or isomers thereof.
2. The method of claim 1 , wherein the fatty liver disease is alcohol related liver disease (ARLD) or -nonalcoholic fatty liver disease (NAFLD).
3. The method of claim 2 , wherein the alcohol related liver disease is selected from alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH) and alcoholic cirrhosis.
4. The method of claim 2 , wherein the nonalcoholic fatty liver disease is selected from nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis.
5. The method of claim 1 , wherein each R 1a is C 1-6 haloalkyl.
6. The method of claim 1 , wherein each R 1a is independently selected from the group consisting of H, Me, Et, F, CL, or —CF 3 .
7. The method of claim 1 , wherein each R 1a is —CF 3 .
8. The method of claim 1 , wherein R 2 is H.
9. The method of claim 1 , wherein the compound of Formula Id is selected from the group consisting of:
10. The method of claim 1 , the compound of Formula Id having the formula:
11. The method of claim 1 , wherein said compound of Formula Id is an antagonist of the glucocorticoid receptor.
12. The method of claim 1 , wherein said compound of Formula Id is an antagonist of the mineralocorticoid receptor.
13. The method of claim 1 , wherein said compound of Formula Id inhibits glucocorticoid binding to the glucocorticoid receptor and is an antagonist of the mineralocorticoid receptor.
14. The method of claim 1 , wherein said compound of Formula Id inhibits glucocorticoid binding to the glucocorticoid receptor with an inhibition constant (K i ) of between about 0.0001 nanomolar (nM) to 1000 nM and is an antagonist of the mineralocorticoid receptor.
15. The method of claim 13 , wherein said fatty liver disease is an alcoholic-related fatty liver disease.
16. The method of claim 14 , wherein said fatty liver disease is an alcoholic-related fatty liver disease.
17. The method of claim 13 , wherein said fatty liver disease is a nonalcoholic fatty liver disease.
18. The method of claim 14 , wherein said fatty liver disease is a nonalcoholic fatty liver disease.
19. The method of claim 17 , wherein said nonalcoholic fatty liver disease is selected from nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis.
20. The method of claim 18 , wherein said nonalcoholic fatty liver disease is selected from nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis.